Recent Research press releases & news

Presswire is the leading news platform where businesses, educational institutions, news reporters, etc. come together to share compelling news stories that transform opinions and impact lives. Presswire has an extensive media contact list for press releases, reaching millions of contacts. We ensure that your story lands on the right business desks and the right mass media outlets. To begin your press release distribution, send your stories to Presswire or by filling out the form here.

1

 

[PRESSWIRE] Vienna, Austria - 02.05.2003 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of the positive results of a Phase 2 clinical study that tested azelastine nasal spray as a new approach for reducing viral load in the nose of SARS-CoV-2 positive patients in the peer-reviewed journal Scientific Reports (1).

1

 

[PRESSWIRE] Nairobi - November 9, 2022 -- The Digital Innovations and Diagnostics for Infectious Diseases in Africa (Didida) had its official kick-off at the Strathmore University. Didida is an ambitious project to develop reliable, low-cost, mobile phone-connected tests to help detect multiple infectious diseases and non-communicable diseases (NCD) at once in sub-Saharan Africa. Didida also plans to invest in digital health infrastructure and train a new generation of African experts to meet the health needs of the continent.

1

 

[PRESSWIRE] London, UK - 30.09.22 -- COPTRZ Ltd, have launched their new drone learning experience platform (LXP) platform COPTRZ ACADEMY. COPTRZ claim that this is the leading platform of its type anywhere in the World.

1

 

[PRESSWIRE] Austria - 04.07.22 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent inhibitor of major variants of SARS- CoV-2 in the peer-reviewed journal Frontiers in Pharmacology (1).

1

 

[PRESSWIRE] LUBBOCK, TX -- April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.

1

 

[PRESSWIRE] Vienna - 23rd February 2022 -- Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, today announces the publication of positive Phase I data with ShigETEC, its vaccine candidate against Shigellae and enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines10020340).

1

 

[PRESSWIRE] Austria - 10.12.21 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).

1

Red Devil, Jan Vertonghen co-invests in Ghent-based scale-up to expand groundbreaking epilepsy AI technology to sleep and other neurological disorders...

 

[PRESSWIRE] Austria - 04 May, 2021 -- CEBINA GmbH, an Austrian biotech company, today announces that azelastine, previously identified as a potential anti-COVID-19 drug, is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus. Azelastine is available as an anti-allergy nasal spray and is currently being tested in a Phase 2 efficacy trial for the treatment of early-stage COVID-19 disease.

1

[PRESSWIRE] SANTA ANA, January 26, 2021 -- Airionex, the leading global provider of bi-polar ionization air and surface purification technology, announced today that it has hired Françoise Parker as Senior Vice President of Sales and Marketing. Françoise will report to CEO Jukka Matikka, and will be responsible for sales team leadership, accelerating Airionex revenue throughout North America, the development and management of key channels, and overseeing the company’s marketing strategy.